Rapid development of glomerular injury and renal failure in mice lacking p53R2

Pediatric Nephrology

Volumn 20, Issue 3 SPEC. ISS., 2005, Pages 432-440

  Powell, David R ^a   Desai, Urvi ^a   Sparks, Mary Jean ^a   Hansen, Gwenn ^a   Gay, Jason ^a   Schrick, Jeff ^a   Shi, Zheng Zheng ^a   Hicks, John ^b   Vogel, Peter ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Gene trap; Glomerulopathy; Knockout; Nephrotic syndrome; Podocyte

Indexed keywords

PROTEIN P53; RETROVIRUS VECTOR; RIBONUCLEOTIDE REDUCTASE; RNA;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL; CAPILLARY FLOW; CAPILLARY RESISTANCE; CAUSE OF DEATH; CELL LOSS; CELL SIZE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA REPAIR; DYING; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; ENZYME ACTIVE SITE; FAILURE TO THRIVE; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENETIC CODE; GENETIC TRANSCRIPTION; GLOMERULOPATHY; GLOMERULUS CAPILLARY; GROWTH; KIDNEY INJURY; MALE; MOUSE; MOUSE STRAIN; NEPHROTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RNA ANALYSIS; SURVIVAL TIME; VASCULARIZATION; WEANING;

ANIMALS; CELL CYCLE PROTEINS; FEMALE; KIDNEY FAILURE; KIDNEY GLOMERULUS; MALE; MICE; MICROSCOPY, ELECTRON; RIBONUCLEOTIDE REDUCTASES; TIME FACTORS;

EID: 14644442937     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1696-5     Document Type: Article

References (30)

1. Zambrowicz BP, Turner CA, Sands AT (2003) Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 3:563-570 10.1016/j.coph.2003.04.002
2. Zambrowicz BP, Sands AT (2003) Knockouts model the 100 best-selling drugs - Will they model the next 100? Nat Rev Drug Discov 2:38-51
3. Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT (1998) Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392:608-611 10.1038/33423
4. Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A (2001) In vivo drug target discovery: Identifying the best targets from the genome. Curr Opin Biotechnol 12:626-631
5. BeltrandelRio H, Kern F, Lanthorn T, Oravecz T, Piggott J, Powell D, Ramirez-Solis R, Sands AT, Zambrowicz B (in press) In: Carroll P (ed) Model organisms in drug discovery. Wiley & Sons, Chichester, UK
6. Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP (2002) Full-speed mammalian genetics: In vivo target validation in the drug discovery process. Trends Biotechnol 20:36-42 10.1016/S0167-7799(01)01843-1
7. Wattler S, Kelly M, Nehls M (1999) Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 26:1150-1156, 1158, 1160
8. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT (2003) Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100:14109-14114
9. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42-49 10.1038/35003506
10. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647-40651 10.1074/jbc.M106088200
11. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34:440-445 10.1038/ ng1212
12. Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR (2001) Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21:4829-4836 10.1128/MCB.21.14.4829-4836.2001
13. Council NR (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC
14. Tinsley FC, Taicher GZ, Heiman ML (2004) Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. Obes Res 12:150-160
15. Silver J, Keerikatte V (1989) Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J Virol 63:1924-1928
16. Benigni A, Remuzzi G (1996) Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 16:151-159
17. Nagata M, Tomari S, Kanemoto K, Usui J, Lemley KV (2003) Podocytes, parietal cells, and glomerular pathology: The role of cell cycle proteins. Pediatr Nephrol 18:3-8 10.1007/s00467-002-0995-y
18. Ghiggeri GM, Carraro M, Vincenti F (2004) Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: Theory and therapy. Nephrol Dial Transplant 19:1036-1040 10.1093/ndt/gfh173
19. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 43:368-382 10.1053/j.ajkd.2003.10.024
20. Stan RV, Tkachenko E, Niesman IR (2004) PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol Biol Cell 15:3615-3630 10.1091/mbc.E03-08-0593
21. Stan RV, Ghitescu L, Jacobson BS, Palade GE (1999) Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. J Cell Biol 145:1189-1198 10.1083/jcb.145.6.1189
22. Kriz W, Elger M, Mundel P, Lemley KV (1995) Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 5:1731-1739
23. Satchell SC, Anderson KL, Mathieson PW (2004) Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15:566-574
24. Eremina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9-15
25. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716 10.1172/JCI200317423
26. Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369-2379
27. Tryggvason K (1999) Unraveling the mechanisms of glomerular ultrafiltration: Nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10:2440-2445 1:CAS:528:DyaK1MXnsVegsb8%3D
28. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349-354 10.1038/74166
29. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251-256 10.1038/73456
30. Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR (2004) Alpha-actinin-4-mediated FSGS: An inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2:E167